Affiliation:
1. Division of Endocrinology, Beth Israel Hospital Boston, Massachusetts
2. Joslin Diabetes Center Boston, Massachusetts
Abstract
To examine potential interactions between leptin and the β3 adrenergic system in the regulation of food intake, we determined the effects of treatment with a selective β3 adrenergic receptor (AR) agonist (CL 316,243 [1 mgfleg]) on body weight, food intake, and leptin expression. Studies were carried out in C57B1/6J and FVB male control mice as well as in mice with targeted disruption of the β3 AR gene. These findings were correlated with measurement of the expression in hypothalamus of neuropeptide Y (NPY) and melanin concentrating hormone (MCH), two neuropeptides that may be involved in the central regulation of food intake. Treatment with CL 316,243 (1 mg/kg) for 12 or 24 h decreased leptin mRNA abundance and circulating levels to 20% of baseline in normal animals. No effect of the CL 316,243 compound was seen in mice with targeted disruption of the β3 AR gene. Despite the falling leptin levels, β3 agonist administration acutely suppressed food intake. Finally, the induced suppression of food intake and leptin levels occurred despite unchanged or increased hypothalamic expression of the orexigenic neuropeptides NPY and MCH. Thus, β3 AR agonists via β3 ARs suppress leptin levels acutely and simultaneously suppress food intake via a mechanism that operates downstream of leptin and two of its putative central targets.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
180 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献